Zogenix (ZGNX) Q4 EPS In Line

Zogenix, Inc. (ZGNX) reported fourth quarter EPS of ($0.13) in the extended session Tuesday, compared to the consensus estimate of ($0.13). Revenues increased 50.5% from last year to $14.9 million. Analysts expected revenues of $12.76 million. Net product revenue was $5.0 million, compared to $9.0 million in the fourth quarter 2013.

For the full-year 2014, the company reported total revenues of $40.5 million, up 23% from $33.0 million in the full year 2013. Net product revenue came in at $21.7 million, compared to $31.7 million yoy.

Separately, Zogenix today announced an agreement to sell Zohydro(R) ER Business to Pernix for $100 million plus regulatory and sales milestones up to $283.5 million.

On valuation measures, Zogenix Inc. shares, which currently have an average 3-month trading volume of 3.37 million shares, trade at a P/E to growth ratio of (0.12). The median Wall Street price target on the name is $2.50 with a high target of $3.50. Currently ticker boasts 4 ‘Buy’ endorsements, compared to no ’Holds’ and no ‘Sell’.

Profitability-wise, ZGNX has a t-12 profit and operating margin of (18.31%) and (243.67%), respectively. The $255.58 million market cap company reported $42.2 million in cash in its most recent quarter.

ZGNX currently prints a one year loss of about 57.67% and a year-to-date return of around 24.82%.

The chart below shows where the equity has traded over the last 52 weeks.

Zogenix Inc. is a pharmaceutical company, developing therapies that address specific clinical needs for people living with CNS disorders. The firm was founded in 2006 and is headquartered in San Diego, California.

Be the first to comment

Leave a Reply

Your email address will not be published.